Skip to content

Greencare Capital - 2021 Final Results


Announcement provided by

MaxRets Ventures Plc · MAX

26/04/2022 07:00

Greencare Capital - 2021 Final Results
RNS Number : 3389J
Greencare Capital PLC
26 April 2022
 

26 April 2022                                                      

 

Greencare Capital plc

("Greencare" or the "Company")

 

Final Results for the Year Ended 31 October 2021

 

Greencare (AQUIS: GRE), the investment company focused on investing in medicinal cannabis, CBD and related wellness areas, announces its final results for the year ended 31 October 2021.

 

Extracts of the Company's audited report and accounts can be found below. A full copy of the final results, which should be read in full, will shortly be available from the Company's website and will be sent to all shareholders.

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

Enquiries:

 

Greencare Capital plc

Richard Tonthat, CEO

 

+44 7786 377489

Cairn Financial Advisers LLP

AQSE Corporate Adviser

Jo Turner / James Lewis

 

+44 20 7213 0880

 

 

 

 

Walbrook PR Limited

Paul Vann/Nick Rome

 

+44 20 7933 8780

+44 7768 807631

greencarecapital@walbrookpr.com

 

 

Greencare Capital plc

CEO's Statement

for the year ended 31 October 2021

 

Introduction

Greencare Capital plc (the "Company" or "Greencare") is an enterprise company quoted on the Aquis Stock Exchange Growth Market ("AQSE"). The Company was incorporated on 1 October 2019 and its shares were admitted to trading on 30 December 2019.

 

The Company's investment strategy is to focus on the changing regulatory environment surrounding legal medicinal cannabis within countries that have well-developed and reputable laws and regulations for its production, research and distribution as well as investment opportunities within the hemp and CBD wellness sectors and other plant-based medicines. The law and regulation surrounding the cannabis sector, however, is constantly evolving.  The Company's investments, where applicable, will only focus on companies and businesses with activities that are lawful in the jurisdiction in which they take place and are either already lawful or are capable of being lawful in the UK. The Directors therefore believe that such activities should not amount to any offences under the POCA 2002 in the UK.

 

The Company invests directly or indirectly in public or private companies, in supply and distribution chains, or other businesses associated with the sector. Investments may take the form of debt or equity and it is expected that investment will ordinarily seek capital growth in the medium term in preference to income generating opportunities.

 

The Company identifies investment opportunities in the cannabis sector predominantly in Europe. The Directors believe that there are numerous investment opportunities within the wellness industry as well as fast-growing production, distribution and other associated businesses that will be of interest to the Company. The Directors will not invest in the recreational cannabis sector, or in entities or activities supported by the recreational sector, or any other related activities which would be deemed illegal under UK legislation.

 

Investments during the year

During the period under review, the Company has continued to review various investment opportunities and, on 31 March 2021 it announced that it had agreed to invest £100,000 in Clearly Supplements Limited ("Clearly"), as part of a £500,000 fund raising.  The investment is by way of a convertible loan note ("CLN") with a 5 per cent. coupon and a 12-month duration. The CLN is expected to convert at the time of a public listing at a 30 per cent. discount to the placing price at that time, subject to a maximum price of £157.50.

 

Clearly has developed a full range of products under the Clearly CBD brand. It is also establishing a number of distribution channels which include direct sales channels, and the Board is pleased to note that Clearly now has approximately 80 direct sellers, who are being trained and supported.  Clearly intends to increase this number significantly during 2022. It is also focused on certain other key market segments such as the fitness sector and, at the same time, will be looking to build a retail presence and to operate online. Clearly has also entered into a supply agreement with Hempflax International, Europe's largest independent hemp grower and processor.

 

Clearly is planning its own stock market listing in the short term.

 

On 23 April 2021, the Company agreed to make another equity investment of £100,000 in Voyager Life Limited ("Voyager"), as part of a £671,000 fund raising by Voyager.

 

Voyager, a health and wellness business focused on CBD and hemp seed oil, has developed a range of products under the Voyager and Voyager Life brands, including oils, gummies, bath and skincare products and is already generating revenues. It is currently developing a number of distribution channels which include direct sales, drop shipping, specialist retailers and online marketplaces.

 

On 30 June 2021, Voyager announced that it had completed its own IPO and admission to trading on The AQSE Growth Market, with Greencare holding approximately 2.8 per cent. of the enlarged issued share capital of Voyager at the time of flotation. Voyager now has approximately 32 formulated products, approximately 90 total stock keeping units available across its website and three retail stores in Scotland. With sales increasing, a strong product portfolio, broad distribution strategy and the company well capitalised, we look forward to further positive trading updates from Voyager.

 

The Board continues to believe the CBD sector has significant potential, with the UK being one of the world's largest and fastest growing markets for CBD products. The Board, however, is also cognisant that the CBD sector has not performed well recently and the latest developments with novel foods legislation in the UK, whilst providing clarity, is likely to cause short to medium term turbulence as companies are required to adapt.  Within Europe, novel foods legislation is still to be agreed and has been much slower than initially anticipated.  This makes cannabis and CBD investments within Europe very difficult. 

 

As such, the Board considers it will continue to explore further investments in CBD and cannabis cautiously, as well as looking at related health, wellness and plant based medicine investments.

 

Board Changes

Since publication of the Company's 2020 Final Results in April 2021, Fabio Carretta and Nicholas Lee have both stepped down from the board to focus on their other business interests. Both departed the Company with the Board's thanks and best wishes. I was appointed to the board in May 2021 as CEO, and Monica Formenti was appointed as a non-executive director in September 2021.

 

The Board intends to align itself with the activities of the Company and its chosen investment areas and therefore may look to make further directorate changes as opportunities present themselves.

 

Outlook

Greencare continues to actively pursue additional investment and acquisition opportunities of varying sizes in the cannabis and CBD space, however, it does so cautiously. It also anticipates it will take a broader view in the medium term, or until such time as the sector shows stability, than it has been doing to include related health, wellness and plant based medicine investments as per its strategy.

 

The Directors believe that Greencare is well placed to deploy funds in line with the Company's stated investment strategy and looks forward to updating the market further in the near future.

 

 

Richard Tonthat

Chief Executive Officer

25 April 2022

 

  

 

Statement of Comprehensive Income

For the period ended 31 October 2021

 

 

 

 

 

 

 

 

2021

£'000

13-month period ended 31 October

2020

£'000

 

 

 

 

 

 

 

 

Administrative expenses

 

(376)

(427)

 

 

 

 

Operating loss

 

(376)

(427)

 

 

 

 

Interest income

 

3

-

 

 

 

 

Loss before tax

 

(373)

(427)

 

 

 

 

Taxation

 

-

-

 

 

 

 

Loss for the financial year

 

(373)

(427)

 

 

 

 

Other comprehensive income for the year

 

-

-

 

 

 

 

Total comprehensive loss

 

(373)

(427)

 

 

 

 

 

 

 

 

Earnings/(loss) per share (pence) from continuing operations attributable to owners of the Company - Basic & Diluted

 

(0.03)

(0.04)

 

 

 

 

Statement of Financial Position

As at 31 October 2021

 

 

2021

£'000

2020

£'000

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

Financial assets

 

164

-

 

 

164

-

Current assets

 

 

 

Trade and other receivables

 

62

38

Cash and cash equivalents

 

878

1,463

Total current assets

 

940

1,501

 

 

 

 

Total assets

 

1,104

1,501

 

Current liabilities

 

 

 

Trade and other payables

 

54

80

Total current liabilities

 

54

80

 

 

 

 

Net assets

 

1,050

1,421

 

 

 

 

Capital and reserves

 

 

 

Share capital

 

148

148

Share premium

 

1,587

1,587

Share based payment reserve

 

115

113

Retained earnings

 

      (800)

     (427)

Total equity

 

1,050

1,421

 

 

Statement of Changes in Equity

For the year ended 31 October 2021

 

 

Share capital

Share premium

Share based payment reserve

Retained earnings

 

Total

 

£'000

£'000

£'000

£'000

£'000

 

 

 

 

 

 

As at 1 October 2019

-

-

-

-

 

Loss for the year

-

-

-

(427)

(427)

 

 

 

 

 

 

Total Comprehensive Income

-

-

-

(427)

(427)

 

 

 

 

 

 

Issue of shares

148

1,834

-

-

1,982

Share issue costs

-

(138)

-

-

(138)

Share based payments

-

(109)

113

-

4

 

 

 

 

 

 

Total Transactions with Owners

148

1,587

113

-

1,848

 

 

 

 

 

 

As at 31 October 2020

148

1,587

113

(427)

1,421

Loss for the year

-

-

-

(373)

(373)

 

 

 

 

 

 

Total Comprehensive Income

-

-

-

(373)

(373)

 

 

 

 

 

 

Share based payments

-

-

2

-

2

 

 

 

 

 

 

Total Transactions with Owners

-

-

2

-

2

 

 

 

 

 

 

As at 31 October 2021

148

1,587

115

(800)

1,050

 

 

Statement of Cash Flows

For the year ended 31 October 2021

 

 

 

 

 

 

 

2021

£'000

13-month period ended 31 October

2020

£'000

 

 

£'000

£'000

 

 

 

 

Cash from operating activities

 

 

 

Loss before tax

 

(373)

(427)

 

 

 

 

Adjustments for:

 

 

 

 

 

 

 

Interest income

 

(3)

-

Share based payment charge

 

2

4

Change in value of financial assets

 

39

-

(Increase)/decrease in trade and other receivables

 

(24)

(38)

Increase/(decrease) in trade and other payables

 

(26)

80

Net cash used in operating activities

 

(385)

(381)

 

 

 

 

Cash flows from financing activities 

 

 

 

Proceeds from issue of shares (net of issue costs)

 

-

1,844

Net cash from financing activities

 

-

1,844

 

 

 

 

Cash flows from investing activities 

 

 

 

Purchase of investments

 

(200)

-

Net cash from investing activities

 

(200)

-

 

 

 

 

Net cash flow for the year

 

(585)

1,463

 

 

 

 

Cash and cash equivalents at beginning of year

 

1,463

-

Cash and cash equivalents at end of year

 

878

1,463

Net change in cash and cash equivalents

 

(585)

1,463

 

 

 

Notes to the financial statements

For the year ended 31 October 2021

 

 

1. General information

 

Greencare Capital plc is a public limited company limited by shares and was incorporated in England on 1 October 2019 with company number 12237710. Its registered office is 5 Fleet Place, London, EC4M 7RD.

 

The Company's shares are traded on the Aquis Stock Exchange Growth Market under ticker ECP and ISIN number GB00BJBYK814. 

 

The Company's investment strategy is to focus on investments in Cannabis sectors within countries that have well-developed and reputable laws and regulations for its production, research and distribution; and the CBD and Hemp sectors.

 

The financial statements present the year to 31 October 2021. The comparatives present the 13 month period from 1 October 2019 to 31 October 2020.

 

2. Basis of Preparation

The financial statements of Greencare Capital plc have been prepared in accordance with U.K. Adopted International Financial Reporting Standards in conformity with the Companies Act 2006 ('Adopted IFRS').

 

These financial statements are prepared on a going concern basis, under the historical cost convention, as modified by the recognition of listed investments at fair value.

 

The financial statements are presented in Pounds Sterling, which is the Company's presentation and functional currency, and are presented in £'000 unless otherwise stated.

 

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. The areas involving a higher degree of judgment and complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 3 to the financial statements.

 

3. Going Concern

As at 31 October 2021, the Company had cash of £0.88 million. As an investment business, the Company has limited operating cash flow and is dependent on the performance of its investments and its cash balances for its working capital requirements. Annualised normal running costs of the Company are circa £0.3 million. As at the date of this report, the Company had approximately £0.74 million of cash at bank.

 

The Directors are therefore of the opinion that the Company has adequate financial resources to enable it to continue in operation for the foreseeable future. For this reason, it continues to adopt the going concern basis in preparing the financial statements.

 

The Company's employees can carry out their duties remotely, via the network infrastructure in place. As a result, there was no disruption to the operational activities of the Company during the COVID-19 social distancing and working from home restrictions. All key business functions continue to operate at normal capacity. 

 

4. Earnings per share

 

2021

£'000

2020

£'000

Earnings

 

 

Loss for the period

(373)

(427)

 

 

 

Number of shares

 

 

Weighted average number of shares for the purposes of basic and diluted earnings per share

14,792,374

10,714,296

 

 

 

Earnings per share (pence)

(0.03)

(0.04)

 

 

Earnings per share (pence)

(0.04)

       

 

5.   Dividends

The Directors do not recommend payment of a dividend for the period ended 31 October 2021.

 

 

6.   Annual General Meeting (AGM)

The Directors will inform shareholders of the arrangements for the AGM in a separate announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXGUGDSRXDDGDL ]]>

View more ...

MAX announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal